Pharmadrug Inc.
PHRX
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -102.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -102.97% |
| Cost of Revenue | -- | -- | -- | -- | -100.00% |
| Gross Profit | -- | -- | -- | -- | 100.00% |
| SG&A Expenses | 47.44% | 30.11% | 22.22% | -32.69% | -59.57% |
| Depreciation & Amortization | 7,933.33% | 6,400.00% | 253.09% | 21.38% | -103.33% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.30% | 12.24% | 8.48% | -43.12% | -67.37% |
| Operating Income | -37.30% | -12.24% | -8.48% | 43.12% | 67.35% |
| Income Before Tax | -1,065.21% | -1,044.04% | -723.75% | -328.54% | 121.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -894.24% | -1,153.74% | -758.93% | -322.36% | 123.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 17.01% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,037.85% | -663.22% | -92.47% | -45.43% | 88.84% |
| EBIT | -37.30% | -12.24% | -8.48% | 43.12% | 67.35% |
| EBITDA | -32.25% | -9.57% | -7.61% | 43.55% | 62.68% |
| EPS Basic | -699.38% | -436.84% | -33.53% | -1.87% | 89.47% |
| Normalized Basic EPS | -28.57% | -31.65% | -2.38% | 48.19% | 78.98% |
| EPS Diluted | -737.42% | -453.75% | -34.73% | -1.71% | 90.03% |
| Normalized Diluted EPS | -28.57% | -31.65% | -2.38% | 48.19% | 78.98% |
| Average Basic Shares Outstanding | 84.18% | 57.94% | 34.11% | 13.18% | 2.15% |
| Average Diluted Shares Outstanding | 84.18% | 57.94% | 34.11% | 13.18% | 2.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
